The CLL Research Consortium (CRC) is multi-institutional research program with a mission to develop improved and potentially curative treatments for patients with chronic lymphocytic leukemia (CLL). The CRC provides an infrastructure that facilitates research on novel therapies and on clinical-laboratory relationships that improve clinical staging and/or assist in the early assessment of response to therapy. The CRC has six projects. Proj, 1 (Croce) investigates the genetic basis for CLL and examines the expression and function of non-coding RNA found to influence pathogenesis and disease progression. Proj, 2 (Reed) examines novel chemical antagonists that target proteins that inhibit apoptosis. Proj, 3 (Kipps) examines strategies for active immune therapy, factors involved in the cross talk in the CLL-cell microenvironment, and novel approaches to target R0R1, a leukemia-associated antigen. Proj. 4 (Gribben) evaluates T cell defects that impair cognate intercellular interactions and/or development of effective anti-tumor immunity and investigates strategies for allogeneic stem cell transplantation. Proj. 5 (Plunkett) examines the activity of promising anticancer agents alone or in mechanism-based combinations. Proj. 6 (Grever) studies inhibitors of key metabolic pathways implicated in pathogenesis and/or disease progression. The CRC has 4 cores: Core A (Kipps) provides scientific and administrative oversight, organizes meetings, facilitates communication, monitors for compliance with regulatory agencies, and provides biomedical informatics and data management. Core B (Neuberg) assists in the design, implementation, and data analyses of basic and clinical research projects. Core C (Rassenti) provides for tissue banking, sample trafficking, and sample validation. It ensures uniform analyses of genetic and phenotypic features of stored samples, processes samples from patients treated on CRC clinical studies, and ensures appropriate access to samples for correlative science studies and hypothesis-testing research. Core D (Wierda) facilitates development and execution of clinical trials, identifies new strategies for treatment, facilitates correlative laboratory studies, and assesses laboratory and clinical parameters collected on patients participating in CRC clinical studies.

Public Health Relevance

This program is studying chronic lymphocytic leukemia (CLL), the most common adult leukemia in the U.S. Research projects on genetics and biology of CLL are integrated in an infrastructure that facilitates discovery and initial validation of novel approaches to treat patients with this incurable disease. Success in these efforts is anticipated to have major implications to our understanding and treatment of cancer in general.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081534-14
Application #
8733424
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (O1))
Program Officer
Merritt, William D
Project Start
1999-05-01
Project End
2017-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
14
Fiscal Year
2014
Total Cost
$3,769,923
Indirect Cost
$551,788
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Kashyap, Manoj K; Kumar, Deepak; Jones, Harrison et al. (2016) Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 7:2809-22
Lamothe, Betty; Wierda, William G; Keating, Michael J et al. (2016) Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res 22:4712-26
Oakes, Christopher C; Seifert, Marc; Assenov, Yassen et al. (2016) DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 48:253-64
Balatti, Veronica; Acunzo, Mario; Pekarky, Yuri et al. (2016) Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer 2:134-143
Lampson, Benjamin L; Kasar, Siddha N; Matos, Tiago R et al. (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128:195-203
Salzer, Elisabeth; Cagdas, Deniz; Hons, Miroslav et al. (2016) RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nat Immunol 17:1352-1360
Dhar, Sachin; La Clair, James J; León, Brian et al. (2016) A Carbohydrate-Derived Splice Modulator. J Am Chem Soc 138:5063-8
Hawkins, Edwin D; Duarte, Delfim; Akinduro, Olufolake et al. (2016) T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 538:518-522
Sarkar, Aloke; Balakrishnan, Kumudha; Chen, Jefferson et al. (2016) Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 7:3461-76
Thompson, Philip A; O'Brien, Susan M; Xiao, Lianchun et al. (2016) β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122:565-73

Showing the most recent 10 out of 440 publications